Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMB-01 in Combination With Chemotherapy in Unresectable or Metastatic Colorectal Cancer
NCT07649655Phase 1Recruiting
- Sponsor
- EpimAb Biotherapeutics
- Start
- Sep 2026
- Primary completion
- Mar 2028
- Countries
- 1
01
Overview
Phase 1, open-label trial of emb-01 in colorectal cancer (CRC) (4 arms), sponsored by EpimAb Biotherapeutics. Primary endpoints: Adverse Events, Dose-Limiting Toxicities and 2 more. Started Sep 2026; status: recruiting.
02
Drugs
emb-01
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07649655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07649655.